Cilengitide (EMD121974) in Combination With Whole Brain Radiotherapy in Patients With Brain Metastases From Lung Cancer - a Single-Center, Open-Label Phase I Study.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cilengitide (Primary)
Indications Cancer metastases; Non-small cell lung cancer; Small cell lung cancer
Focus Adverse reactions
Acronyms CIRAB

07 May 2024 Status changed from recruiting to completed.
03 May 2010 Planned end date changed from 1 Feb 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
20 May 2009 Trial acronym (CIRAB) added as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com